A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF MODAKAFUSP ALFA (TAK-573) AS A SINGLE AGENT IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
- Registry ID
- TAK-573-1501
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2022-10-07
- Last update
- 2022-05-06
Conditions
- RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Related clinical trials
- A PHASE 3 RANDOMIZED STUDY COMPARING JNJ-79635322 AND AN ANTI-BCMAXCD3 BISPECIFIC ANTIBODY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR LINES OF THERAPY INCLUDING A PI, AN IMID, AND AN ANTI-CD38 ANTIBODY
- A PHASE III OPEN-LABEL, RANDOMISED, MULTICENTRE STUDY COMPARING AZD0120, A DUAL-TARGETING AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DIRECTED AGAINST BCMA AND CD19, VERSUS STANDARD REGIMENS IN PARTICIP WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (DURGA-4)
- A PHASE 1B/2A, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED
DOSE AND SCHEDULE, AND EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF
MEZIGDOMIDE IN COMBINATION WITH ELRANATAMAB IN PARTICIPANTS WITH RELAPSED
AND/OR REFRACTORY MULTIPLE MYELOMA
- A PHASE 1/2 STUDY OF ETENTAMIG IN COMBINATION WITH A CELMOD AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF ANITOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- A FIRST-IN-HUMAN, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE THE SAFETY, ANTITUMOR
ACTIVITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS SAR446523,
AN ANTI GPRC5D ADCC-ENHANCED MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA
View on source registry